847615-14-9

Usage

Uses

Used in Pharmaceutical Synthesis:
TERT-BUTYL 4-(4-BROMOPHENYL)-4-CYANOPIPERIDINE-1-CARBOXYLATE is used as a building block in the synthesis of pharmaceutical compounds for its unique structural features that can contribute to the development of new drugs.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, TERT-BUTYL 4-(4-BROMOPHENYL)-4-CYANOPIPERIDINE-1-CARBOXYLATE is utilized for its potential to enhance the properties of drug candidates, given its specific chemical structure and reactivity.
Used in Drug Discovery:
TERT-BUTYL 4-(4-BROMOPHENYL)-4-CYANOPIPERIDINE-1-CARBOXYLATE is employed in drug discovery processes to identify and develop new therapeutic agents, capitalizing on its biological activities and potential therapeutic properties.
Note: Since the provided materials do not specify particular industries or detailed applications beyond the general fields of pharmaceutical synthesis, medicinal chemistry, and drug discovery, the uses are listed in broad terms. If more specific applications or industries are identified in future research or materials, they can be added to the list accordingly.

Upstream product

• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 16532-79-9 4-Bromophenylacetonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 401518-11-4 [(tert-butoxycarbonyl)imino]diethane-2,1-diyl dimethanesulfonate 

Downstream Products

• 1255666-69-3 4-(4-bromophenyl)piperidine-4-carbonitrile 
• 1492686-35-7 C₁₂H₁₅BrN₂O 
• 913542-81-1 4-(4-bromo-phenyl)-piperidine-1,4-dicarboxylic acid mono-(9H-fluoren-9-ylmethyl)ester 
• 913542-82-2 4-(4-bromo-phenyl)-4-chlorocarbonyl-piperidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 913542-80-0 4-(4-bromo-phenyl)-piperidine-4-carboxylic acid 
• 917925-61-2 4-(4-bromo-phenyl)-4-carbamoyl-piperidine-1-carboxylic acid tert-butyl ester 
• 917925-62-3 tert-butyl 4-amino-4-(4-bromophenyl)piperidine-1-carboxylate 
• 917899-11-7 4-[4-(1-dimethylsulphamoyl-3-methyl-1H-pyrazol-4-yl)-phenyl]-4-(3-methoxy-phenoxymethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 917899-07-1 4-(4-bromo-phenyl)-4-hydroxymethyl-piperidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 917899-08-2 4-bromomethyl-4-(4-bromo-phenyl)-piperidine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 
• 917899-12-8 4-(3-methoxy-phenoxymethyl)-4-[4-(3-methyl-1H-pyrazol-4-yl)-phenyl]-piperidine 
• 917899-09-3 4-(4-bromo-phenyl)-4-(3-methoxy-phenoxymethyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant

A series of AKT inhibitors possessing a piperidin-4-yl side chain was designed and synthesized. Some of them showed high AKT1 inhibitory activity and potent anti-proliferative effect on PC-3 prostate cancer cells in the preliminary screening. Further studies revealed the most potent compound, 10h, as a pan-AKT inhibitor. Compound 10h was able to inhibit the cellular phosphorylation of AKT effectively and induce apoptosis of PC-3 cells. It also showed high metabolic stability in human liver microsomes. Preclinical characterization of 10h, a promising lead AKT inhibitor, as a potential anti-prostate cancer therapeutic needs to be further investigated.

Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity

Targeting of Akt has been validated as a well rationalized approach to cancer treatment, and represents a promising therapeutic strategy for aggressive hematologic malignancies. We describe herein an exploration of novel Akt inhibitors for cancer therapy through structural optimization of previously described 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives. Our studies yielded a novel series of pyrrolopyrimidine based phenylpiperidine carboxamides capable of potent inhibition of Akt1. Notably, 10h exhibited robust antiproliferative effects in both mantle cell lymphoma cell lines and primary patient tumor cells. Low micromolar doses of 10h induced cell apoptosis and cell cycle arrest in G2/M phase, and significantly downregulated the phosphorylation of Akt downstream effectors GSK3β and S6 in Jeko-1 cells.

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

A nitrogen-containing heterocyclic phenyl piperidine compound and its preparation method and application

The invention discloses a nitrogen-containing heterocyclic phenyl piperidine compound or pharmaceutical salt thereof. The general structural formula a of the compound is as shown in specification, wherein R represents hydrogen, mono-substituted or poly-substituted halogen, methyl, methoxyl, tertiary butyl or trifluoromethyl; and R2 is hydrogen, chlorine, bromine, methyl or ethyl. The compound disclosed by the invention is novel in structure; and by introducing the active amino in the form of a piperidine ring, the configuration of the side-chain amino is reinforced and the rigidity of the compound is enhanced. Through the design transformation, the Akt1 kinase inhibitory activity and the PC-3 cell line growth inhibitory activity of the compound are significantly enhanced.

TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

AROMATIC COMPOUND

An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof: , wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G1, G2, G3, G4 and G5 are CH or N, X is -NH-, -O-, -CH2-, etc., Y is - CH2-,-CO-,-SO2- etc., Z is a single bond, -CO-, -SO2-, -NH-, -O-, -S-, -CONH-,-SO2NH-, etc., R2 is hydrogen, alkyl, alkoxy, halogen, etc., and R3 is carbocyclic group, heterocyclic group, alkyl, etc., is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.

ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS

The invention provides a compound of the formula (II): or a salt, solvate, tautomer or N-oxide thereof; wherein n is 0 or 1; one of Y1 and Y2 is CH and the other is selected from CH, CR8 and N; q is 0, 1 or 2 provided that q is 0 or 1 when Y1 or Y2 is CR8; R1 is an aryl or heteroaryl group of 5 to 10 ring members; R2a and R3a each are hydrogen, C1-4 hydrocarbyl or C1-4 acyl wherein the hydrocarbyl and acyl moieties are optionally substituted by fluorine, hydroxy, amino, methylamino, dimethylamino or methoxy; or NR2aR3a forms an imidazole group or a saturated monocyclic 4-7 membered heterocyclic group optionally containing a second heteroatom ring member selected from O and N; R18 is hydrogen or methyl; R19 is hydrogen or methyl; R24 is hydrogen or R24, R2a and the intervening nitrogen atom and carbon atoms together form an azetidine, pyrrolidine or piperidine ring; R25 is hydrogen or a C1-4 alkyl group wherein the C1-4 alkyl group is optionally substituted by hydroxy or amino provided that there are at least two carbon atoms between the hydroxy or amino group and the oxygen atom to which R25 is attached; and R4 and R5 each are hydrogen or a substituent as defined in the claims

2-Substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

The present invention discloses compounds of formula I wherein Ar, Y, m, n, R1 and R4 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.